Metastatic Breast Cancer

  • Jessica C. Gooch
  • Freya SchnabelEmail author


Metastatic breast cancer is considered an incurable disease although survival has improved in recent years with the advent of newer systemic therapies. Five-year survival is typically quoted as 26%. After a thorough workup including full-body imaging and biopsy of suspected metastatic sites, the patient should be initiated on systemic therapy. Local treatments including surgery and radiation are reserved for palliative purposes. Patients may progress through several lines of therapy. Involvement of palliative care and hospice teams in the multidisciplinary approach is key as is attention to quality of life issues.


Metastatic Systemic therapy Palliation Quality of life 


  1. 1.
    Barinoff J, et al. Primary metastatic breast cancer in the era of targeted therapy – prognostic impact and the role of breast tumour surgery. Eur J Cancer. 2017;83:116–24.CrossRefGoogle Scholar
  2. 2.
    Surveillance, E.a.E.R.P. Cancer stat facts: female breast cancer. In: Cancer stat facts. National Cancer Institute Surveillance, Epidemiology and End Results Program (SEER). 1975–2014.Google Scholar
  3. 3.
    Kaklamani V, Gradishar WJ. Endocrine therapy in the current management of postmenopausal estrogen receptor positive metastatic breast cancer. Oncologist. 2017;22:507–17.CrossRefGoogle Scholar
  4. 4.
    Mariotto AB, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809–15.CrossRefGoogle Scholar
  5. 5.
    Network, N.C.C. NCCN- evidence blocks – recurrent or stage IV disease. In: NCCN guidelines version 2.2016 – invasive breast cancer. Fort Washington. National Comprehensive Cancer Network; 2016. p. 17–23.Google Scholar
  6. 6.
    Leung AM, et al. Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res. 2010;161(1):83–8.CrossRefGoogle Scholar
  7. 7.
    Ruiterkamp J, et al. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol. 2009;35(11):1146–51.CrossRefGoogle Scholar
  8. 8.
    Ruiterkamp J, Ernst MF. The role of surgery in metastatic breast cancer. Eur J Cancer. 2011;47:S6–S22.CrossRefGoogle Scholar
  9. 9.
    Budach W. Radiotherapy in patients with metastatic breast cancer. Eur J Cancer. 2011;47:S23–7.CrossRefGoogle Scholar
  10. 10.
    Van Poznak C, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2015;33(24):2695–704.CrossRefGoogle Scholar
  11. 11.
    Lin NU, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22(3):203–10.CrossRefGoogle Scholar
  12. 12.
    Cardoso F, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101(17):1174–81.CrossRefGoogle Scholar
  13. 13.
    Stockler M, et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000;26(3):151–68.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of SurgeryNYU Langone Health, NYU Perlmutter Cancer CenterNew YorkUSA

Personalised recommendations